Objective: The objective of this study was to report the tolerability and toxicity of a regimen consisting of intravenous (IV) docetaxel and intraperitoneal (IP) cisplatin and paclitaxel with granulocyte colonystimulating factor support.
T
he American Cancer Society's annual projections for ovarian cancer include 22,440 new cases with 14,080 women expected to die from ovarian cancer within the United States. 1 Traditionally, advanced stage disease has been treated with primary cytoreductive surgery followed by intravenous (IV) platinum and taxane-based chemotherapy. 2 Alternative treatment regimens have included the use of both dose dense paclitaxel and platinum [3] [4] [5] as well as the use of a combination of both IV and intraperitoneal (IP) therapy. [6] [7] [8] Attention has been focused on IP administration of antineoplastic agents because of the intra-abdominal dissemination pattern of ovarian cancer, and has been evaluated in a series of trials by the Gynecologic Oncology Group (GOG). [6] [7] [8] While the first 2 trials, GOG104 and 114, were considered positive trials, the improvement in overall survival was somewhat modest at the expense of added toxicity. 6, 8 However, GOG172 demonstrated the clear superiority of an IP and IV chemotherapy regimen when compared with an IV regimen alone in the primary treatment of stage III optimally cytoreduced epithelial ovarian or primary peritoneal carcinoma. 7 GOG172 reported a 23.8-month progression-free survival (PFS) and 65.6-month overall survival (OS) for patients receiving IP chemotherapy as compared with 18.3-month PFS and 49.7-month OS for patients in the IV treatment group. These trial results prompted a US National Cancer Institute (NCI) Clinical Announcement in 2006 encouraging IP chemotherapy as the preferred method of treatment for these women. 9 Importantly, the rates of both grade 3 and 4 leukopenia (76% vs. 64%, P < 0.001) and neurological events (19% vs. 9%, P = 0.001) were more common in the patients receiving the IV/IP regimen.
Despite this endorsement and the subsequent support from numerous other multidisciplinary professional societies, adoption of IP chemotherapy use has been slow. Notable barriers include the need for coordinated multidisciplinary care, high toxicity, catheter-related issues, inpatient administration, and limited access to facilities with experience providing such therapy. 9 Catheter-related complications and patient unwillingness to continue therapy are also potential obstacles. Secondary to side effects, only 42% of the patients receiving the IP arm in GOG172 were able to complete all assigned cycles. 7 Other studies have demonstrated similar findings. 10 Most recently, the GOG reported preliminary findings from GOG252 (NCT01167712), a phase III trial evaluating a modification of the GOG172 regimen with a lower dose of IP cisplatin versus 2 dose dense, or weekly paclitaxel regimens, one with IV carboplatin, and the second with IP carboplatin, all in combination with bevacizumab induction and maintenance. 11 Preliminary data demonstrated no survival benefit for either of the IP therapy arms with median PFS survival ranging from 26.8 to 28.7 months for the 3 arms. Moreover, Wright et al 12 utilized the MarketScan database and noted that IP therapy was used in only 15% of patients and that in the absence of a confirmatory trial in the United States, dose dense paclitaxel appears to be increasing. However, 2 reports from ASCO 2016 note continued utility of IP regimens in ovarian cancer patients traditionally excluded from IP trials, namely those having a suboptimal cytoreduction as well as following an interval cytoreduction. 13, 14 In an effort to reduce toxicity and increase rates of therapy completion, modifications of the GOG172 regimen have been reported. 10, 15 We adopted a modified outpatient regimen consisting of IV docetaxel 75 mg/m 2 , IP cisplatin with a fixed dose of 75 mg/m 2 and IP paclitaxel 60 mg/m 2 as our primary IP therapy regimen. Compared with paclitaxel, docetaxel has been shown to have a different side effect profile with less neuropathy at the expense or more neutropenia and without a detriment in quality of life for patients, all without sacrificing PFS or OS. 16 The objectives for this study are to report: (1) our docetaxelbased IP regimen protocol; (2) toxicity and tolerability of this regimen; (3) early outcomes including response rate and PFS. Eligible patients included those with stages II-IV epithelial ovarian, fallopian tube, and peritoneal carcinoma. Patients who received this regimen as primary adjuvant therapy (N = 52) or following interval debulking surgery (N = 8) were included. All patients had GOG performance status of 0 to 1 and adequate renal, hepatic, and bone marrow function before initiation of therapy.
MATERIALS AND METHODS
ABSTRACTed data included patient demographics, medical comorbidities, and oncologic history including histology, grade, stage, and surgical details. Data were collected regarding the timing of IP port placement and related complications. Charts were reviewed for chemotherapy cycles planned and received, adverse events, and any treatment delays, dose reductions, or hospitalizations. Toxicity data regarding hematologic, gastrointestinal, metabolic, renal, neurological, infectious and embolic events was collected. Grading of toxicity was based on the National Cancer Institute Common Toxicity Criteria Version 2. Response to the treatment regimen was noted to be complete, partial, or progression as documented by the treating physician. Patients without a response were considered to have no PFS time. PFS and OS were calculated from the date of surgery. Recurrence was based on one of the following: Gynecologic Cancer Intergroup Criteria for Ca-125 from the nadir, 17 radiographic imaging, or physical examination. Patients without evidence of progression were censored at the time of their last clinic visit. Disease status at time of last clinic visit was recorded. Patients known to be deceased were considered to have died from their cancer. When date of death was not documented in the patient's chart, public death records were utilized.
The modified regimen in this study is based on a proposed 21-day cycle with therapy on D1 and D8 for a total of 6 cycles. The details of the regimen are outlined in Table 1 . The primary modifications include substitution of D1 docetaxel for paclitaxel as well as administration of IP cisplatin on D1 in an ambulatory setting. The dose of cisplatin was reduced to 75 mg/m 2 from the 100 mg/m 2 used in GOG172. All patients were given granulocyte-colony stimulating factor with pegfilgrastim 6 mg subcutaneously on D8. Pretreatment laboratories were routinely checked before D1 and D8 of treatment. Additional IV fluids were not routinely administered following cisplatin administration although they were added to the regimen if patients experienced significant renal dysfunction or dehydration.
The treating physician, before the initiation of IP therapy, determined the number of planned cycles of IP therapy. Dose reductions, delays, and alterations were also made at the discretion of the treating physician. Dose alterations included omission of D8 treatment or failure to complete D1 therapy for any reason. IP cycles were considered completed once the patient received D1 of the cycle. If IP chemotherapy was stopped before completion of the planned number of cycles, the patient continued with IV therapy alone on a standard 21-day cycle to complete therapy as tolerated. Descriptive and summary statistics were determined and Kaplan-Meier estimates of survival were compared with the Log Rank test (SPSS version 22, IBM Corporation, Armonk, NY).
RESULTS

Patient Characteristics
Sixty patients received at least 1 cycle of IP therapy, and were included. Patients were predominantly white (78%) with a median age of 63 (range, 29 to 77 y). Most patients, 38 (63%), had stage IIIC disease at the time of initial cytoreductive surgery. Nearly all patients were at least optimally debulked (97%) and 33% had no residual disease. Bowel resection was performed in 40% of patients. Papillary serous (69%) was the most common histology. A majority (60%) of patients had delayed placement of their IP catheter. Eight patients (13%) received at least 1 cycle of neoadjuvant IV chemotherapy. Complete patient and disease characteristics are depicted in Table 2 . Table 3 lists the incidences of grade 3 or 4 toxicity. A total of 18% of patients received therapy without experiencing 
Toxicity and Tolerability
Prechemotherapy IV medications: dexamethasone, diphenhydramine, fosaprepitant, palonosetron, and ranitidine Intraperitoneal paclitaxel 60 mg/m 2 , to gravity in 1 L 0.9% saline flushed with 500 mL 0.9% saline and administered over 1 hsignificant toxicity. Neutropenia (47%), gastrointestinal (28%) and anemia (25%) were most frequently encountered. Other commonly observed toxicities included neurological (17%) and renal (10%). Thrombocytopenia, metabolic derangements, thromboembolic events, and infection were all less frequent. Four patients (7%) experienced neutropenic fever. Twentythree hospitalizations were documented among 18 patients during IP therapy. One patient was hospitalized for an IP port infection following cessation of IP therapy. No patients suffered death as a result of toxicity.
Complications related to the IP port were relatively uncommon with most patients (85%) experiencing no IP port-related complications. Infection (8%) was the most common port-reported toxicity, although only 1 patient required removal. The remaining infections were treated with oral antibiotics. Other complications included 2 port fractures (3%), 1 port that failed to function (2%) and 1 port occluded with a thrombus (2%). One patient suffered a bowel injury during laparoscopic placement and required laparotomy to repair. Table 4 demonstrates the tolerability of therapy. Of 328 total IP cycles prescribed, patients were able to complete 80%. Two-thirds of patients were able to complete all prescribed IP cycles. Six IP cycles were prescribed for 45 patients (75%). 56% of those patients completed all 6, and median number of IP cycles received was 4. For the patients unable to complete all prescribed IP cycles, only 2 were unable to complete at least 6 cycles of IV chemotherapy.
Efficacy
Delay in therapy > 1 week was required in 12 patients (20%), with 1 patient requiring 2 separate delays. Six patients (10%) required dose-reduction due to toxicity, most commonly from renal dysfunction. Thirty-eight dose alterations were made in 25 patients (42%), most frequently due to neutropenia (18 total alterations). Less commonly observed indications for alteration included renal (7 alterations) and gastrointestinal (5 alterations). IP therapy was stopped due to toxicity in 33% of patients. No patients stopped due to progression; however, 1 stopped due to a plateau in response as measured by her Ca-125 level. Nearly all patients (88%) demonstrated a complete response to therapy, and only 3 patients (5%) had progressive disease during therapy. At the time of data analysis, 43% of patients were without evidence of disease, 23% were alive with disease, 27% were deceased, and the status of 7% was unknown. Median PFS was 25.5 months (95% CI, 20.4-30.5 mo), while OS was 56.8 months (95% CI, 47.7-65.9 mo) (data not shown). When considering the 44 patients with stage III disease, median PFS was 22.1 months (95% CI, 16.3-28.0 mo) and is depicted in Figure 1 , while median OS was 56.8 months (95% CI, 47.3-66.3 mo) and is depicted in Figure 2 . 
DISCUSSION
Following the publication of GOG172, which demonstrated an improvement in OS of 16 months for patients that received any IP chemotherapy compared with IV therapy alone, the utilization of IP chemotherapy received increased attention; however, patients receiving IP therapy experienced greater toxicity. In an attempt to limit potential toxicity, we adopted a docetaxel-based regimen of IP chemotherapy designed to improve tolerability and transition the regimen to an ambulatory setting, while still preserving the survival benefit.
We previously described our early experiences in a multi-institutional study with this regimen, although patients previously may have received cisplatin 100 mg/m 2 IP and amifostine administration was omitted. 15 This is based on published data, demonstrating similar efficacy but improved neurotoxicity and quality of life scores in women with advanced epithelial ovarian cancer. 16, 18 However, docetaxel was also associated with higher rates of neutropenia and neutropenic complications. 16, 18 Recognizing the high rate of neutropenia in GOG172, the substitution of an agent with higher bone marrow suppression justified the addition of primary prophylactic granulocyte-colony stimulating factor. This limited neuropathic toxicity to 17% while also minimizing neutropenic complications. Per institutional protocol, these patients received their pegfilgrastim injections on D8 following their paclitaxel infusions, a practice demonstrated to be safe in gynecologic cancer patients. 19 Since the start of 2008, 60 of our patients with advanced ovarian, fallopian tube or primary peritoneal carcinoma have received at least 1 cycle of this outpatient docetaxel-based IP chemotherapy regimen. We demonstrated excellent tolerability of this regimen among a broad population of patients including those with stage 2, 3, and 4 disease, suboptimally debulked patients, and those treated with neoadjuvant chemotherapy. As part of the treatment protocol, we also checked hematologic parameters before the day 8 infusion, although this approach was not utilized in GOG172. Neutropenia was responsible for half the instances where patients missed D8 treatment, and was the most common reason for dose alteration. This conservative approach of utilizing results from D8 laboratories before treatment may have contributed to the improvements in safety and tolerability of therapy compared with GOG172; however, it may have resulted in unnecessary treatment modifications, as an abnormal laboratory value was primarily responsible for twothirds of the instances where D8 treatment was missed. On the basis of the data presented here, we have further modified our protocol to eliminate routine hematologic monitoring before D8 paclitaxel. The incidence of neutropenia appears reasonable when considering just 14% of neutropenic patients experienced the comorbidity of fever.
Major side effects of platinum-based chemotherapy include renal, metabolic, and gastrointestinal symptoms. 20 The IP therapy arm in GOG172 experienced a significant increase in gastrointestinal (46% vs. 24%) and metabolic toxicities (27% vs. 7%), in addition to an increase in renal toxicity (7% vs. 2%). 7 We addressed these potential toxicities by reducing the IP cisplatin dose from 100 to 75 mg/m 2 , and using an aggressive antiemetic regimen of daily dexamethasone on D0 and D2 to D5 in addition to dexamethasone, diphenhydramine, fosaprepitant, palonosetron, and ranitidine on D1 and D8. The combination of antiemetics used was aimed at preventing both acute and delayed emesis. Severe gastrointestinal and metabolic toxicities were observed in just 28% and 5% of patients, respectively, rates comparable to those observed in the IV therapy arm of GOG172. 7 Overall, toxicity appeared to be favorable with thrombocytopenia, thromboembolic events and infection observed in 7% or fewer patients. Other infrequent toxicities included hearing loss and fatigue or weakness. Ten percent suffered severe renal toxicity. No patients experienced death as a result of complications from treatment. Hospitalizations were infrequent, occurring just 23 times total. Half of those occurred during or after cycle 1, and intractable nausea and emesis was the most common cause. Low rates of complications early in IP therapy may prevent conversion to less demanding IV therapy. Likewise, dose delays (13 total occurrences) and reductions (10% of patients) were infrequent, and are felt to be a direct result of the changes made to our regimen. Comparable statistics are not available from GOG172.
Treatment with IP chemotherapy carries a unique set of complications due to the presence of an intraperitoneal catheter. Comparable to GOG172, the IP port was placed during the debulking surgery in 40% of patients. During the initial adoption, delayed placement was preferred. This pattern has changed with time, and placement during the primary debulking surgery is now the preferred method at our institution. IP port complications were rare, and led to just 3 patients (5%) discontinuing IP therapy. This compares favorably with GOG172, which found that 34% of patients discontinued IP therapy mainly due to catheterrelated complications. 21 As seen in multiple other studies, infection was the most frequently observed complication. 22 IP therapy was tolerated remarkably well by our patients. The completion rate of IP cycles prescribed was 80%, and 65% of patients were able to complete all prescribed IP cycles. A smaller joint institutional study, including our institution, performed in 2009 examined outcomes from a similar outpatient regimen and reported that 71% of patients had to discontinue therapy before completion. 15 Here, toxicity was short lived and did not typically prevent patients from completing IP therapy. This led to excellent response rates, with 88% of patients having complete response and just 5% experiencing progression. GOG172 utilized second-look laparotomy as an option to determine pathologic response, and found that 57% of patients experienced a complete response within 8 weeks. Whereas GOG172 was a large multicenter phase 3 randomized control trial, our current study is limited to a single institutional experience. Other potential biased include its retrospective design, small patient population, relatively short follow-up and potential confounding, which may all impact our results. Moreover, physician bias may help explain decisions to enroll in patients on a clinical trial versus the use of the outpatient docetaxel regimen. Nonetheless, during the study period the described outpatient docetaxel regimen was the preferred regimen for patients not treated on a clinical trial and for the 44 patients with stage III disease, was associated with a median PFS of 22.1 months (95% CI, 16.3-28.0 mo) with median OS 56.8 months (95% CI, 47.3-66.3 mo).
In conclusion, this modified IP chemotherapy regimen is safe and well tolerated, which resulted in reduced rates of severe toxicity compared with GOG172, no treatment-related patient deaths, and promising preliminary survival data. As noted by more recent publications, data still supports the use of IP chemotherapy in patients with advanced ovarian cancer. By moving treatment to an outpatient setting and improving the toxicity profile, we anticipate our ability to treat patients will improve, as will our institutional survival rates. Further investigation into this docetaxel-based regimen is warranted.
